| Literature DB >> 28587078 |
Aline Carla Inada1, Priscila Silva Figueiredo2, Rosângela Aparecida Dos Santos-Eichler3, Karine de Cássia Freitas4, Priscila Aiko Hiane5, Alinne Pereira de Castro6, Rita de Cássia Avellaneda Guimarães7.
Abstract
Cultural and economic shifts in the early 19th century led to the rapid development of companies that made good profits from technologically-produced commodities. In this way, some habits changed in society, such as the overconsumption of processed and micronutrient-poor foods and devices that gave rise to a sedentary lifestyle. These factors influenced host-microbiome interactions which, in turn, mediated the etiopathogenesis of "new-era" disorders and diseases, which are closely related, such as obesity, type 2 diabetes mellitus, non-alcoholic fatty liver disease, hypertension, and inflammatory bowel disease, which are characterized by chronic dysregulation of metabolic and immune processes. These pathological conditions require novel and effective therapeutic approaches. Morindacitrifolia (noni) is well known as a traditional healing plant due to its medicinal properties. Thus, many studies have been conducted to understand its bioactive compounds and their mechanisms of action. However, in obesity and obesity-related metabolic (dysfunction) syndrome, other studies are necessary to better elucidate noni's mechanisms of action, mainly due to the complexity of the pathophysiology of obesity and its metabolic dysfunction. In this review, we summarize not only the clinical effects, but also important cell signaling pathways in in vivo and in vitro assays of potent bioactive compounds present in the noni plant which have been reported in studies of obesity and obesity-associated metabolic dysfunction.Entities:
Keywords: Morinda citrifolia L.; health; obesity; obesity-related metabolic dysfunction
Mesh:
Year: 2017 PMID: 28587078 PMCID: PMC5490519 DOI: 10.3390/nu9060540
Source DB: PubMed Journal: Nutrients ISSN: 2072-6643 Impact factor: 5.717
Principal phytochemicals from Morinda citrifolia as bioactive compounds against obesity and obesity-related metabolic dysfunction.
| Part of Plant | Structural Class | Bioactive Compounds | Concentrations of Bioactive Compounds | References |
|---|---|---|---|---|
| Fruit | Phenolic acid | Chlorogenic acid | 10.49 mg/100 mL [ | [ |
| Gentisic acid | 19.16 mg/100 mL [ | [ | ||
| P-hydroxybenzoic acid | 14.12 mg/100 mL [ | [ | ||
| Flavonoids | Anthocyanin (cyanidin-3- | Data not shown | [ | |
| Catechin | 53.68 mg/g [ | [ | ||
| Epicatechin | 6.8 mg/g [ | [ | ||
| Kaempferol | 6.4 mg/g [ | [ | ||
| Rutin | 8.06 mg/g [ | [ | ||
| Quercetin | 7.4 mg/g [ | [ | ||
| Iridoids | Asperulosidic acid | Data not shown | [ | |
| Lignans | Americanin A | 17.4 mg [ | [ | |
| Americanol A | 21 mg 60] | [ | ||
| Isoprincepin | 14 mg [ | [ | ||
| Lirioresinol B | Data not shown | [ | ||
| Lirioresinol B dimethyl ether | Data not shown | [ | ||
| Morindolin | 10 mg [ | [ | ||
| 3,3’-Bisdemethypinoresinol | 69 mg [ | [ | ||
| Coumarins | Scopoletin | 46.1 mg [ | [ | |
| Minerals | Potassium | 3900 mg/L [ | [ | |
| Triterpenoids/terpenes | Ursolic acid | Data not shown | [ | |
| Saponin | Data not shown | [ | ||
| Vitamins | Vitamin C | Data not shown | [ | |
| Vitamin E | Data not shown | [ | ||
| Leaf | Flavonoids | Catechin | 63.46 mg/g [ | [ |
| Epicatechin | 23.08 mg/g [ | [ | ||
| Rutin | 6.83 mg/g [ | [ | ||
| Kaempferol | 21–80 mg [ | [ | ||
| Triterpenoids/terpenes | Ursolic acid | Data not shown | [ | |
| Root | Anthraquinones | 1,2-Dimethoxyanthraquinone | 3.5 mg [ | [ |
| Alizarin-2-methyl ether | 11.3 mg [ | [ | ||
| Rubiadin-1-methyl ether | 15.5 mg [ | [ | ||
| Lucidin 3- | Data not shown | [ | ||
| Damnacanthol-3- | Data not shown | [ | ||
| Morindone-6- | Data not shown | [ | ||
| Iridoid | Asperulosidic acid | Data not shown | [ | |
| Deacetylasperulosidic acid | Data not shown | [ |
Principal bioactive compounds from fruits, leaves, and roots of Morinda citrifolia used for obesity and obesity-related metabolic dysfunction.
The effects of administration of the Morinda citrifolia L. plant on obesity.
| Host | Part of Plant | Dose/Time | Effects | Reference |
|---|---|---|---|---|
| Mice | Fruit Noni Juice | 1.5 µL/g body weight (twice daily)/5 weeks | −Reduced body weight by 40% in mice fed control, while reduced body weight by 25% in HFD mice. | Nishioka et al. [ |
| −Reduced adipose tissue weights, plasma triglycerides and improved glucose tolerance. | ||||
| Rats | Fruit Noni Juice | 50 mg/kg/day/30 days | −Reduced body weight (better at 50 mg/kg/day dose). | Shoeb et al. [ |
| −Reduced serum total cholesterol, triglycerides and lipid fractions: LDL and VLDL (all doses). | ||||
| 100 mg/kg/day/30 days | −Increased lipid fraction HDL (all doses). | |||
| Mice | Fruit Fermented Noni Juice | 1.5 µL/g body weight/twice daily/12 weeks | −Inhibited weight gain after 12 weeks. | Nerurkar et al. [ |
| −Improved glucose and insulin tolerance and fasting glucose in HFD-fed C57Bl/6 mice. | ||||
| −Improved hepatic insulin resistance by FOXO-1 and inhibition of PEPCK and G6P (gluconeogenic enzymes). | ||||
| Hamster | Fruit Noni Juice | −3 mL (containing 64.23 mg crude polysaccharides/kg body weight/6 weeks. | −Decreased visceral fat in HFD-hamsters (all doses). | Lin et al. [ |
| −Decreased serum and liver lipids: total cholesterol and triglycerides in HFD hamsters (all doses). | ||||
| −6 mL (containing 128.46 mg crude polysaccharides/kg body weight/6 weeks. | −Beneficial effects on liver and hepatic enzymes (ALT) in HFD hamsters (all doses). | |||
| −Increased antioxidant capacity in the liver in HFD hamsters (all doses). | ||||
| −9 mL (containing 192.69 mg crude polysaccharides/kg body weight/6 weeks) | −Decreased inflammatory biomarkers in the liver (TNF-α, MCP-1, IL-1β) in HFD hamsters (all doses). | |||
| −Decreased gelatinolytic levels of MMP9 in HFD hamsters (all doses). | ||||
| Rats | Ethanolic Extract of Leaves | −250 mg/mL/9 weeks. | −Prevented weight gain, especially MLE 60 500 mg/kg. | Jambocus et al. [ |
| −Positive effects on adiposity, fecal fat content, plasm lipids, insulin and leptin levels, especially MLE 60 500 mg/kg. | ||||
| −500 mg/mL/9 weeks. | −Improved ghreline levels, especially MLE 250 mg/kg. | |||
| −Improvement in metabolic perturbations caused by obesity, both concentrations of extract. | ||||
| In vitro | Ethanolic Extract of Fruit and Leaves | 0.2 mg/mL in vitro | −Inhibited LPL activity. | Pak-Dek et al. [ |
| In vitro | Ethanolic Extract of Fruit | 1 mg/mL in vitro | −Inhibited LPL activity. | Sahib et al. [ |
Effects of administration of different doses and parts of the Morinda citrifolia plant on obesity in in vivo and in vitro studies.
The effects of administration of the Morinda citrifolia L. plant on insulin resistance/type 2 diabetes mellitus (T2DM).
| Host | Part of Plant | Dose/Time | Effects | Reference |
|---|---|---|---|---|
| In vitro | −Isolation of compounds (two new lignans, three new neolignans, and 10 known acid compounds). | −Stimulatory effects on glucose uptake through a fluorescent-tagged glucose probe (2-NBDG) in 3T3-L1 adipocyte cells. | Nguyen et al. [ | |
| −Inhibitory effects on protein tyrosine phosphatase 1B gene (PTP1B), which is overexpressed in insulin resistance. | ||||
| Mice | Fruit (Fermented noni juice). | −1.5 µL/g body weight/twice daily/12 weeks | −Inhibited weight gain after 12 weeks. | Nerurkar et al. [ |
| −Improved glucose and insulin tolerance and fasting glucose in HFD-fed C57Bl/6 mice. | ||||
| −Improved hepatic insulin resistance by FOXO-1 and inhibition of PEPCK and G6P (gluconeogenic enzymes) | ||||
| Mice | −Fruit (15 kg dried noni fruit powder fermented by Cheonggukjang and bacteria). | −fermented noni juice/90 days. | −Reduced fasting glucose levels, glycosylated hemoglobin (HbA1) in KK-Aγ diabetic-mice. | Lee et al. [ |
| −Improved insulin sensitivity in KK-Aγ diabetic-mice. | ||||
| In vitro | −Fruit (70% methanol extract). | −200 and 400 µg/mL in vitro. | −Diminished lipid fraction LDL and triglycerides in KK-Aγ diabetic-mice. | |
| −70% methanol extract in culture cells (C2C12 cells) activated PPAR-γ and stimulated AMPK pathway. | ||||
| Mice | −Roots (methanol extract—soluble phases: CHCl3, EtOAc, | −3 g/kg/single administration. | − | Kamiya et al. [ |
Effects of administration of different doses and parts of the Morinda citrifolia plant on insulin resistance/T2DM in in vivo and in vitro studies.
Effects of the administration of the Morinda citrifolia L. plant on non-alcoholic fatty liver disease (NAFLD).
| Host | Part of Plant | Dose/Time | Effects | Reference |
|---|---|---|---|---|
| Hamster | Fruit noni juice (2.14 g crude polysaccharides/100 mL) | −3 mL (including 64.23 mg crude polysaccharides/kg body weight/6 weeks. | −Diminished visceral fat in HFD-hamsters (all doses). | Lin et al. [ |
| −Lowered serum and liver lipids: total cholesterol and triglycerides in HFD hamsters (all doses). | ||||
| −6 mL (including 128.46 mg crude polysaccharides/kg body weight/6 weeks. | −Beneficial effects on the liver and hepatic enzymes (ALT) in HFD hamsters (all doses). | |||
| −Increased antioxidant capacity in the liver in HFD hamsters (all doses). | ||||
| −9 mL (including 192.69 mg crude polysaccharides/kg body weight/6 weeks). | −Diminished inflammatory biomarkers in the liver (TNF-α, MCP-1, IL-1β) in HFD hamsters (all doses). | |||
| −Lowered gelatinolytic levels of MMP9 in HFD hamsters (all doses). | ||||
| Mice | Fruit fermented noni juice | −1.5 µL/g body weight/twice daily/12 weeks. | −Inhibited weight gain after 12 weeks. | Nerurkar et al. [ |
| −Improved glucose and insulin tolerance and fasting glucose in HFD-fed C57Bl/6 mice. | ||||
| −Improved hepatic insulin resistance by FOXO-1 and inhibition of PEPCK and G6P (gluconeogenic enzymes). |
Effects of administration of different doses and parts of the Morinda citrifolia plant on NAFLD in in vivo studies.
The effects of administration of the Morinda citrifolia L. plant on dyslipidemia.
| Host | Part of Plant | Dose/Time | Effects | Reference |
|---|---|---|---|---|
| Rats | Fruit (Noni juice) | −50 mg/kg/day/30 days. | −Reduced body weight (better at 50 mg/kg/day dose). | Shoeb et al. [ |
| −100 mg/kg/day/30 days. | −Reduced serum total cholesterol, triglycerides, and lipids fractions: LDL and VLDL (all doses). | |||
| −Increased lipid fraction HDL (all doses). | ||||
| Rats Mice | Fruits, leaves and roots (70% ethanolic aqueous extract). | −Fruit ethanol extract (1000 and 500 mg/kg/day). | −All of the extracts on tyloxapol-induced hyperlipidemia: reduced total cholesterol and triglyceride levels. | Mandukhail et al. [ |
| −Leaf ethanol extract (1000 and 500 mg/kg/day). | −MFE in HFD-induced dyslipidemia (1000 mg/kg/day): prevented the rise of serum total cholesterol, LDL, total cholesterol/HDL ratio, and atherogenic index. No significant effects on HDL and glucose levels. No effect on body weight. | |||
| −Root ethanol extract (500 and 300 mg/kg/day) | −MLE in HFD-induced dyslipidemia (1000 mg/kg/day): prevented the rise in serum total cholesterol, LDL, total cholesterol/HDL ratio, atherogenic index, and glucose levels. No significant effects on HDL. Significantly prevented the gain in average body weight. | |||
| −MRE in HFD-induced dyslipidemia (500 mg/kg/day): prevented the rise in serum total cholesterol, LDL, total cholesterol/HDL ratio, atherogenic index, and glucose levels. Increased HDL. Significantly prevented the gain in average body weight. | ||||
| In vitro | Fruit (methanolic extract-soluble phases: CHCl3, EtOAc, nBuOH, H2O). | −Effective EtOAc purified and isolated lignans | −Lignans isolated from EtOAc fraction of methanol extract inhibited activity against copper-induced LDL oxidation by measuring the decrease in TBARS. | Kamiya et al. [ |
| Hamster | Fruit (Fermented Noni Juice). | −3 mL NJ (containing 0.20 g solids/kg body weight)/day/6 weeks. | −Reduced sizes of heart, liver and visceral fat in HFD-cholesterol hamsters. | Lin et al. [ |
| −6 mL NJ (containing 0.40 g solids/kg body weight)/day/6 weeks | −Decreased serum triglycerides, total cholesterol, atherogenic index, malondialdehyde levels and hepatic lipids in HFD-cholesterol hamsters. | |||
| −9 mL NJ (containing 0.60 g solids/kg body weight) /day/6 weeks. | −Increased trolox equivalent antioxidant capacity (TEAC), glutathione (GSH), fecal lipids in HFD-cholesterol hamsters. | |||
| −Downregulated sterol regulator element binding protein-1c (SREBP-1c) and upregulated hepatic peroxisome proliferator-activated receptor-alpha (PPAR-α) and uncoupling protein 2 (UCP-2) mRNA in HFD-cholesterol hamsters. |
Effects of the administration of different doses and parts of the Morinda citrifolia plant on dyslipidemia in in vivo and in vitro studies.
The effects of the Morinda citrifolia plant on hypertension.
| Host | Part of Plant | Doses/Time | Effects | Reference |
|---|---|---|---|---|
| Rats | Fruit and leaf (ethanolic extract) | −Ethanolic extract of leaves (500 mg/kg body weight)/14 days | −Reduced blood pressure in dexamethasone-induced hypertensive rats (all doses and extracts). | Wigati et al. [ |
| −Ethanolic extract of fruit (500 mg/kg body weight)/14 days | −The highest hypotensive effect was with the combination of the extracts. | |||
| −Ethanolic extract of leaves + fruit (1:1, 500 mg/kg body weight)/14 days | ||||
| Rabbit, Rat and Guinea-pig | Roots (70% ethanolic- aqueous extract) | −Different concentrations on rabbit jejunum, thoracic aorta of rats, guinea pig atria in vitro * study. | −Rabbit jejunum: produced concentration-dependent relaxation of spontaneous and high K+-induced concentrations (antispasmodic effect). | Gilani et al. [ |
| −Positive control: verapamil (different concentrations in vitro * study). | −Guinea pig atria: caused inhibition of both atrial force and rate of spontaneous contractions (cardiopressant activity). | |||
| −* Concentration-response curve. | −Rabbit thoracic aorta: suppressed contractions induced by phenylephrine (1.0 µM) in normal –Ca+2 and Ca+2 - free Krebs solution- and by high K+, like the positive control (verapamil). | |||
| −Rat thoracic aorta: also caused relaxation of the phenylephrine (1.0 µM)-induced contractions (vasodilatory activity). | ||||
| Rats | Fruit (noni fruit juice) | −5 mg/kg (single administration after 24 h). | −Increased urine volume in a dose-dependent manner (10 mg/kg higher than 5 mg/kg) | Shenoy et al. [ |
| −10 mg/kg (single administration after 24 h). | −Decreased ion excretion (sodium and potassium) | |||
| −Aquaretic action. |
Effects of administration of different doses and parts of Morinda citrifolia plant on hypertension in in vivo studies. * Studies involving animal tissues in an in vitro assay.
Effects of administration of Morinda citrifolia L. on gut microbiota.
| Host | Methods | Effects | Reference |
|---|---|---|---|
| In vitro | Time courses of lactic acid fermentation of noni juice by | −All reached almost 10 × 108 CFU/mL after 48 h of fermentation at 30 °C | Wang et al. [ |
| In vitro | Human stool sample from a healthy volunteer (10 g) with ethanolic extracts of fermented noni fruit | − | Huang et al. [ |
| Hybrid duck | Supplementation with noni fruit powder using different concentrations | −Increased amount of lactic acid bacteria with supplementation with 2% noni fruit powder; | Kurniawan, Widodo, Djunaidi [ |
| −Decreased |
Effects of administration of Morinda citrifolia on gut microbiota in in vivo and in vitro studies.